EUVIMEDEUVIMED entdecken
Crossref

Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma

Ryo Sato, Yuto Matsushita, Ayana Takemura, Momoko Sugiyama, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Daisuke Motoyama, Masao Nagata, Atsushi Otsuka, Hiroshi Furuse, Hideaki Miyake

Anticancer Research · 2024

DOI: 10.21873/anticanres.16869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Ryo Sato und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan; rsato02@hama-med.ac.jp. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antineoplastic Agents, Kidney Neoplasms, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAntineoplastic AgentsKidney NeoplasmsHypertensionPyridinesHumansProgression-Free SurvivalRetrospective StudiesAnilides

Stichwörter der Autor:innen

Renal cell carcinomaadverse eventcabozantinibprogression-free survival

Substanzen

Antineoplastic AgentscabozantinibAnilidesPyridines

Autor:innen und Institutionen

  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan; rsato02@hama-med.ac.jp.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
  • Department of Developed Studies for Advanced Robotic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Hamamatsu Medical Center, Hamamatsu, Japan.
  • Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Zitieren

APA

Sato, R., Matsushita, Y., Takemura, A., Sugiyama, M., Watanabe, K., Watanabe, H., Tamura, K., Motoyama, D., Nagata, M., Otsuka, A., Furuse, H., & Miyake, H. (2024). Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.16869

Vancouver

Sato R, Matsushita Y, Takemura A, Sugiyama M, Watanabe K, Watanabe H, et al. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.16869

BibTeX
@article{Sato2024,
  author = {Sato, Ryo and Matsushita, Yuto and Takemura, Ayana and Sugiyama, Momoko and Watanabe, Kyohei and Watanabe, Hiromitsu and Tamura, Keita and Motoyama, Daisuke and Nagata, Masao and Otsuka, Atsushi and Furuse, Hiroshi and Miyake, Hideaki},
  title = {Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16869}
}
Kostenlos starten →